. The USEPA (2017) BBDR model extends previously peer-reviewed perchlorate models to describe the relationship between perchlorate exposure and thyroid hormone levels during early pregnancy. Our evaluation focuses on two key elements of the USEPA (2017) report: the plausibility of BBDR model revisions to describe control of thyroid hormone production in early pregnancy and the basis for linking BBDR model results to neurodevelopmental outcomes. While the USEPA (2017) BBDR model represents a valuable research tool, the lack of supporting data for many of the model assumptions and parameters calls into question the fitness of the extended BBDR model to support quantitative analyses for regulatory decisions on perchlorate in drinking water. Until more data can be developed to address uncertainties in the current BBDR model, USEPA should continue to rely on the RfD recommended by the NAS (USEPA, 2005) when considering further regulatory action.
Introduction
From a regulatory perspective, the critical effect of concern from exposure to perchlorate is disruption of thyroid function and the potential for thyroid-hormone-related effects on neurodevelopment in gestation; these effects represent downstream events resulting from competitive inhibition of iodide uptake by the perchlorate ion (USEPA, 2002) . Based on an analysis of the mode of action for perchlorate, the United States Environmental Protection Agency (USEPA) (2002) determined that inhibition of thyroid iodide uptake could be used as an obligatory precursor for these critical effects in a harmonized cancer/ noncancer risk assessment for perchlorate (Fig. 1) . This mode-of-action directed risk assessment approach was used in the derivation of the current Reference Dose (RfD) for perchlorate of 0.0007 mg/kg/day (USEPA, 2005) . Following the recommendations of the National Academy of Sciences National Research Council (NRC) (2005) , the point of departure (POD) for this RfD was a reported No Observed Effect Level (NOEL): a non-statistically significant mean of 1.8% (standard error of the mean 8.3%) decline in radioactive iodine uptake (RAIU) in healthy adults following two weeks exposure to a daily perchlorate dose of 0.007 mg/kg/day (Greer et al., 2002 ). An intraspecies uncertainty factor of 10 was applied to protect the most sensitive population, the fetuses of pregnant women who might have hypothyroidism or iodide deficiency.
Subsequently, the USEPA Office of Drinking Water (2008) published an Interim Health Advisory Level for perchlorate of 15 μg/L, based on the USEPA (2005) RfD of 0.7 μg/kg/day, as recommended by the NRC (2005) . Determination of this Interim Health Advisory Level considered Physiologically-Based Pharmacokinetic (PBPK) Modeling (Clewell et al., 2007) to estimate the potential effect of perchlorate on iodide uptake in several sensitive subgroups, including the pregnant woman and fetus, the lactating woman and neonate, and the young child. Despite widespread scientific acceptance of iodide inhibition as an obligatory precursor to downstream toxicity endpoints, there was remaining concern regarding the level of protection for the population perceived to have the greatest susceptibility -the fetuses of Over the next several years, the focus of research on perchlorate shifted to the development of a biologically based dose-response (BBDR) model of the hypothalamic-pituitary-thyroid (HPT) axis that could be linked with the PBPK model of perchlorate and iodide to predict dose-dependent interactions of perchlorate with iodine hormone homeostasis as a function of iodide intake in an effort to more quantitatively account for the effects of low dietary iodide intake and hypothyroidism in pregnant women on fetal development (McLanahan et al., 2008 (McLanahan et al., , 2009 Fisher et al., 2012; George, 2017a, 2017b; Lumen et al., 2013 Lumen et al., , 2015 .
The USEPA Science Advisory Board ((SAB 2013)) report on perchlorate in drinking water supported the utility of BBDR modeling to help characterize the potential for neurological effects from perchlorate exposure:
"As perchlorate research continues, studies in animals may provide important insights into the neurobehavioral consequences of perchlorate exposure. A physiologically-based pharmacokinetic/pharmacodynamic framework is well suited to help place these findings in the context of human perchlorate exposure."
The USEPA SAB (2013) identified a number of areas for improvement or modification of the existing models. However, they also noted that "Models can always be improved, but the goal is to have a model that is fit for the intended purpose.", apparently cautioning against perpetual model refinement at the expense of implementation, echoing the concern of the renowned statistician, George E.P. Box, who famously used to say: "All models are wrong but some are useful" (Box, 1976) .
Recently, the USEPA's Office of Ground Water and Drinking Water (USEPA, 2017) responded to the Science Advisory Board recommendations and proposed novel approaches to inform the derivation of a Maximum Contaminant Level Goal (MCLG) for perchlorate, including the use of BBDR modeling in their report entitled "Draft Report: Proposed Approaches to Inform the Derivation of a Maximum Contaminant Level Goal for Perchlorate in Drinking Water". This MCLG approach (USEPA, 2017) includes revisions to a previously developed and peer reviewed BBDR model (McLanahan et al., 2008 (McLanahan et al., , 2009 Fisher et al., 2012; George, 2017a, 2017b; Lumen et al., 2013 Lumen et al., , 2015 that was extended to predict the relationship between perchlorate exposure and thyroid hormone levels in sensitive life stages. These revisions aim to address suggestions by the USEPA SAB (2013), including the following:
Derivation of a perchlorate MCLG that addresses sensitive life stages through PBPK/PD modeling; Expansion of the modeling approach to account for thyroid hormone perturbations and potential adverse neurodevelopmental outcomes from perchlorate exposure; Utilization of a mode of action framework for developing the MCLG that links the steps in the proposed mechanism leading from perchlorate exposure through iodide uptake inhibition to thyroid hormone changes and finally neurodevelopmental impacts; and Extension of "the [BBDR] model expeditiously to…provide a key tool for linking early events with subsequent events as reported in the scientific and clinical literature on iodide deficiency, changes in thyroid hormone levels, and their relationship to neurodevelopmental outcomes during sensitive early life stages" (USEPA SAB, 2013, p. 19) .
Model revisions presented in the USEPA (2017) report include: incorporating a description of the physiology of early pregnancy, biological feedback control of hormone production via thyroid-stimulating hormone (TSH) and human chorionic gonadotropin (hCG), and a description of the response to lower levels of iodide nutrition. In addition, an attempt was made to calibrate the model's behavior for upper and lower percentiles of the population, in addition to the population median, for thyroid hormone production. The report also included an uncertainty analysis for key BBDR model parameters.
For the development of the MCLG, USEPA (2017) proposed a twostage approach linking the revised BBDR model results ("Stage 1") with quantitative information on neurodevelopmental outcomes from epidemiological studies ("Stage 2"). Stage 1 describes the thyroidal hormone levels in women of childbearing age with low to adequate iodide intake. In this stage, the revised BBDR model is applied to predict the relationship between perchlorate exposure and changes in thyroid hormone levels in early pregnancy. Data for Stage 2 of the approach is provided from epidemiological studies evaluating maternal thyroid hormone levels in early pregnancy and the relationship between changes in these levels and the observation of neurodevelopmental outcomes. The USEPA (2017) report also described development of a novel population-based approach that uses the revised BBDR model to estimate changes in levels of selected thyroid hormones, specifically free tetraiodothyronine (fT4) and TSH, resulting from perchlorate exposure that may result in an increase in the prevalence of hypothyroxinemia in pregnant women. Hypothyroxinemia (low circulating concentrations of fT4) is often associated with hypothyroidism (low concentrations of fT4 despite increased concentrations of TSH).
The evaluation and (potential) application of the perchlorate BBDR model will serve as an important precedent for future consideration of such models by the agency, as it is only the second such model to be seriously evaluated by USEPA and subjected to external peer-review. The first BBDR model to be considered, formaldehyde nasal carcinogenicity developed by colleagues (2003, 2004) , has been under consideration by the agency for more than a decade. Interest in the use of BBDR modeling in risk assessment peaked in the 1990s when the draft USEPA (2003) Cancer Guidelines identified these models as the preferred option for performing a cancer dose-response. However, since that time, work in this area has waned, possibly due to the perceived difficulty of gaining regulatory acceptance. By their nature, BBDR models are descriptions of complex biological systems that necessarily include significant uncertainty. The challenge going forward will be to develop approaches for characterizing that uncertainty in a risk assessment context and ensuring that these complex models are fit for their intended purpose. It is with this consideration in mind that we have performed a focused evaluation of the proposed USEPA (2017) approaches.
Our critical review focused on two key areas of importance for determining whether the current BBDR model is fit for the purpose of supporting regulatory decisions based on predicted effect of perchlorate exposure on human fetal development:
1. Evaluation of USEPA (2017) model revisions to the peer reviewed BBDR models, including extending the model to early pregnancy, incorporating biological feedback control of hormone production via thyroid stimulating hormone (TSH) and human chorionic gonadotropin (hCG) signaling, calibration of the model for thyroid hormone effects, and uncertainty analysis for key parameters. This evaluation included comparison of model output to results from key human studies identified in previous assessments (Greer et al., 2002 , Braverman et al., 2006 , Téllez Téllez et al. (2005a , 2005b , as well as in the USEPA (2017) document (Steinmaus et al., 2016) ; 2. Evaluation of USEPA (2017) approaches for linking BBDR results to neurodevelopmental outcomes and identification of published literature to develop the quantitative relationship between thyroid hormone levels and neurodevelopmental outcomes; and After describing the results of this evaluation, we present a comparison of the results from the USEPA (2017) approach with results from previous USEPA assessments, in order to put the uncertainties in the BBDR approach in perspective against the potential impact of the new approach on the existing regulatory guidelines for perchlorate USEPA (2005 USEPA ( , 2008 .
Methods
Evaluating Stage 1 of USEPA MCLG approach: Stage 1 of USEPA's MCLG approach relies upon the application of the BBDR model to predict the effect of perchlorate on the thyroid hormone in pregnant women at different iodine nutrition levels, with the goal of predicting fT4 hormone reduction in pregnant women with low dietary iodide. To evaluate the utility of the proposed model to support such predictions, we independently ran the model and tested model predictions against data from multiple studies. These exercises attempted to both duplicate BBDR model results for datasets that were used by USEPA (2017) to calibrate the model and to test the ability of the BBDR model to predict the well-described precursor event inhibition of iodide uptake, which was successfully described with previous versions of the perchlorate PBPK models (Merrill et al., 2003; Clewell et al., 2007) . These simulations included: Steinmaus et al., (2016 In our efforts to produce these simulations, it was noted that instructions provided in the USEPA documentation for running the model for different scenarios, and documentation of the rationale for the model parameter values associated with them, are often inadequate and lack transparency; this deficiency is exacerbated by the number of permutations of parameter settings used in the scripts that generate the results in the document. The complexity of the BBDR model makes it difficult to perform this evaluation, even though it has been conducted by experienced modelers.
Evaluating Stage 2 of USEPA MCLG approach: Stage 2 of USEPA's approach involved evaluating the published epidemiological literature to identify publications that would define quantitative relationships between thyroid hormone levels and neurodevelopmental effects. The USEPA approach was focused on the identification of studies that provided information on levels of fT4 in pregnant mothers during early gestation and the potential for changes in neurodevelopmental outcomes in their offspring. Through targeted literature searching and recommendations from the Science Advisory Board (SAB), a total of 55 studies were identified by USEPA to provide information on altered maternal thyroid hormone levels and offspring development. These studies were divided into three groups to facilitate evaluation:
Group 1 -studies that may be able to quantitatively describe a relationship between incremental alterations in maternal thyroid hormone levels and alternations in offspring development; Group 2 -studies that do not have data from which to derive a quantitative relationship between maternal hormones and offspring neurodevelopment, but instead present only a categorical analysis with thyroid hormones below and above a defined cut point and adverse neurodevelopmental outcomes; and Group 3 -studies that present an analysis that is not directly compatible with BBDR output.
Of the 55 studies, 15 were identified as Group 1, 14 were identified as Group 2, 26 were identified as Group 3. The 15 Group 1 studies were then evaluated further and only 5 were deemed useful by the USEPA for further quantitative analysis to attempt to connect alterations in thyroid hormone levels to alterations in neurodevelopment. in our evaluation, we performed a critical review of the USEPA Stage 2 approach and the study summaries provided in USEPA (2017), considering the most recent recommendations from the National Research Council (NRC, 2014) on systematic review of the literature and evidence integration.
Results

Evaluation of the perchlorate BBDR model for early pregnancy
The draft MCLG approach (USEPA, 2017) is based on a hypothesized mode of action ( Fig. 1) for neurodevelopmental outcomes resulting from development of hypothyroxinemia from perchlorate-induced inhibition of iodide uptake in the thyroid. As noted in USEPA (2017):
"Thyroid hormones are essential for the development and differentiation of the developing brain. The brain and spinal cord begin development in the first half of the first trimester. fT4 passes through the blood-brain barrier via multiple, specific transporter proteins. Next, T4 is converted to T3 by the developing glial cells and then transported to neurons. T3 then interacts with nuclear receptors to tightly regulate gene expression so that neurogenesis, synaptogenesis, neuronal migration, cell differentiation, and myelination are developmentally appropriate. Deficiencies in thyroid hormones through iodine deficiency, congenital hypothyroidism, or maternal hypothyroidism/hypothyroxinemia can result in neurological impairments and intellectual deficits (Morreale de Escobar, Obregón, & Escobar del Ray, 2000) ."
As recommended by the USEPA SAB (2013), the USEPA extended a published BBDR model for perchlorate induced hypothyroxinemia in late gestation (Lumen et al., 2013; George, 2017a, 2017b) to address the sensitive population of concern for exposure to perchlorate: the fetuses of hypothyroxinemic women during early pregnancy (Fig. 2) . These concerns were motivated by new studies (Steinmaus et al., 2016) , suggesting an association between perchlorate exposure and decreased levels of free thyroxine (fT4) in pregnant women. Because the fetus is entirely dependent on maternal thyroid hormones for neurodevelopment in early gestation (Clewell et al., 2007; Howdeshell, 2002) , the endpoint of interest was defined as reduction in maternal fT4 in early pregnancy and the perchlorate BBDR models were extended to describe hormone homeostasis during gestation. Expansion of the original models of perchlorate and iodide (Clewell et al., 2007) to predict the impact of perchlorate exposure on fT4 during early pregnancy, however, is complicated by the significant variability in the levels of fT4 in the general population and the challenges in measuring fT4, as well as the dynamics of changing hormones through the course of gestation and the uncertainty in identifying the level of alteration that may lead to hypothyroidism and fetal effects.
According to the "American Thyroid Association Task force on Thyroid Disease During Pregnancy and Postpartum", isolated hypothyroxinemia is defined as a normal maternal TSH concentration in conjunction with fT4 concentrations in the lower 5th or 10th percentile of the reference range (Stagnaro-Green et al., 2011) . USEPA (2017) has also focused on selected percentiles of the reference range; however, reference ranges can vary from population to population according to the 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum (Alexander et al., 2017) . Even within US populations and across ethnic groups, the 2.5th percentile can vary by up to 2 pmoL/L or approximately 20% (9.3-11.4 pmoL/L as reported by Alexander et al., 2017) . The variation in fT4 reported in the published literature during early pregnancy is provided in USEPA (2017), Appendix A, Figure A -33 and reproduced in Fig. 3 . The levels of fT4 during early pregnancy, based on the studies identified by USEPA (2017), appear to range from (Li et al., 2014; Männistö et al., 2011; Moncayo et al., 2015; Panesar et al., 2001; Zhang et al., 2016) . approximately 13-17 pmoL/L. This range is consistent with the range of baseline fT4 means reported in the Greer et al. (2002) study of approximately 1.1-1.3 ng/dL (14-17 pmoL/L). However, the 50th percentile BBDR model predictions at zero dose perchlorate and 170 μg/ day iodine intake are approximately 10 pmoL/L at gestation weeks 12, 13, and 16, considerably below these reported values.
Measuring fT4 in the presence of high concentrations of bound T4 is challenging, especially in conditions where binding proteins are altered such as during pregnancy (Alexander et al., 2017) . Measurement techniques are prone to inaccuracy during pregnancy due to disruption of the original equilibrium. The 95% fT4 reference intervals decrease gradually with advancing gestational age: from 1.08 to 1.82 ng/dL (approximately 13.9-23.5 pmoL/L) in week 14 to 0.86-1.53 ng/dL (approximately 11.1-19.8 pmoL/L) in week 20 (Alexander et al., 2017) .
Extending the thyroid BBDR model to address early gestation is particularly challenging due to the complex interaction between thyroid homeostasis and gestational development. Considering the addition of TSH feedback dynamics, and an adjustment factor to match specific population percentiles, there is reason for concern regarding the uncertainty of the revised model predictions under low iodide intake conditions. Some of these concerns are highlighted below:
Description of hCG dynamics: Human chorionic gonadotropin (hCG) levels rise in early pregnancy and this in turn increases both sodiumiodide symporter (NIS) uptake activity and T4 production. hCG is structurally similar to TSH and, like TSH, increases thyroidal iodide uptake and thyroid hormone synthesis by binding to the thyroid-stimulating hormone receptor (TSHR) (Hoermann et al., 1994 ). In the model, hCG levels are calculated as a function of gestational age, using an equation for the parameter HCGREG (Fig. 4 , purple curve), and these changing levels are used to increase the rate of T3 and T4 production as a function of the hCG concentration:
The variation of hCG over the duration of gestation is based on direct measurements of hCG in pregnant women (Korevaar et al., 2015) . However, the concurrent increase in thyroidal iodine uptake is described in the model based on an empirical relationship between gestational age in weeks (GW) and radioactive iodide uptake, using an equation for the parameter VCHNG (Fig. 4 , green curve):
Thus the model does not correctly attribute the gestational control of NIS uptake to hCG, when in fact both uptake and hormone synthesis respond to the same changes in hCG (Pesce and Kopp, 2014) . By using different equations for the time-dependence of hCG-stimulated uptake and hormone production (Fig. 4 ) the model decouples processes that are fundamentally linked by their biology. Fig. 4 depicts the timecourse of the parameters controlling changes in iodide uptake (VCHNG) and hCG hormone levels (HCGreg) over the course of gestation. While the biology indicates a proportional relationship between the two parameters, the equations used in the model are not parallel. Elucidating the impact of this decoupling is challenging, and is beyond the scope of this review, since it would have to be investigated at a large number of time-points throughout pregnancy and under different conditions of iodine intake, but the disparity between the model description and the underlying biology justifies caution regarding its predictions of T4 and TSH at different gestational ages, as these parameters govern hormone production and release. We address the impact of the discrepancy between the time-courses for HCGREG and VCHNG in a later section.
Damping of TSH response
The USEPA (2017) BBDR model includes a parameter, pTSH (power to which the ratio of current TSH to the TSH set-point is raised), that reduces the response of the thyroid to increases in TSH:
Using this equation, a pTSH exponent of 0 would represent no control of thyroid function by TSH and an exponent of 1 would represent a linear response of thyroid function to changes in TSH. In their calculations of the effect of perchlorate on the prevalence of hypothyroxinemic pregnant women, the USEPA (2017) use a pTSH exponent of 0.398, which results in a response to TSH that is substantially less than linear, an assumption that is inconsistent with the fundamental biological relationship between TSH and thyroid hormones (production and release of T3 and T4), effectively decoupling a relationship that has been well established in the medical, pharmacological and toxicological communities. USEPA (2017) describes the rationale for this parameter: "The NHANES data do not show a clear correlation between TSH and fT4, so within that data set they vary independently. One could assume, therefore, that individuals with an average fT4 and high TSH have that combination because their thyroid has a weak response to TSH, and vice-versa." To address this concern, USEPA (2017) estimated a lower and upper bound for pTSH as (median TSH)/(97.5th percentile TSH) = 0.398 and (median TSH)/(2.5th percentile TSH) = 3.09, respectively, with a median value of pTSH = 1. Thus, this parameter is used to attempt to represent disease states where the individual's thyroid is either exquisitely sensitive or insensitive to TSH stimulation. At lower values, this parameter reduces the impact of TSH on the Vmax for thyroid iodide uptake as well as the rate constants for T4 and T3 production in the thyroid. However, the USEPA (2017) also states that: "The coefficient, pTSH, is included…to allow for tuning of the strength of the TSH feedback, but in practice model simulations versus data appear quite adequate with pTSH = 1." Concerns about this parameter are two-fold. First, the complexity of the model and various runtime scripts makes it nearly impossible to determine the use of this parameter during some of the model assessment and risk assessment simulations presented in USEPA (2017). Second, using point estimate population level data to define the quantitative temporal relationship between two fundamentally linked processes at the individual level is scientifically inappropriate. To understand the biological feedback within a single individual (i.e. to determine the relationship of TSH to T3/T4 and Vmax for a hypothyroid or hyperthyroid individual), matched samples would be needed for TSH, T3 and T4. This information -to our knowledge -is not available from NHANES. Thus, the epidemiological point estimate data are being used Fig. 4 . Comparison of parameters controlling hCG-dependent changes in thyroidal uptake (VCHNG, green) and thyroid hormone production rate (HCGREG, purple) in the BBDR model as a function of gestational age. Despite the fact that both parameters are dependent upon hCG levels, the predicted trends across gestation are not consistent. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) well beyond its domain of applicability to predict the quantitative outcome of disease states.
Calibration of hormone production rates
The model uses a baseline first-order constant calibrated to NHANES 2007-2012 median, 10th, or 90th percentile non-pregnant data (fT4, fT3, T4 and T3 concentrations). The model parameter for the rate of production of T4 (KProdT4F) for the median NHANES calibration used in USEPA (2017) is 6.25 × 10 -7 /hr/kg 0.75 (their Table A -2), which is 4-fold lower than the value of 2.45 × 10 -6 estimated for the published model (Lumen et al., 2013) , which was based on the data of Nicoloff et al. (1972) . However, the use of a T4 production rate that is lower than the published value is not adequately justified, given the importance of this parameter, which has a direct impact on predictions of fT4 changes, the intended application of the model. This baseline value is then scaled in pregnancy through GW 16 (peak occurring ∼ GW 9) based upon placental hCG increase over this time, according to the linear relationship from Glinoer (1997) : hCGreg = 1 + 0.00354 × hCG.
Affinity of NIS iodine uptake
The model uses a Km for perchlorate binding to the NIS (KmNIS_P) that is 3-fold lower than the value estimated by Lumen et al. (2013) (i.e. a 3-fold higher affinity). Specifically, the new Km represents the 2.5th percentile lower confidence limit of the population median based upon the USEPA (2017) reanalysis of Greer et al. (2002) . The median value (50th percentile = 0.73 μM) is similar to that obtained from a re-analysis of in vitro binding data, 0.59 μM (Schlosser, 2016) ; the use of a value of KmNIS_P = 0.489 μM makes perchlorate 3 times more effective at competitive inhibition of NIS compared to the model of Lumen et al. (2013) . This revision to the Km in USEPA (2017) necessitated revisions to the Vmax (VmaxNISF_thy_P) and urinary excretion parameters (CLFUP) ( Table 1 of USEPA, 2017) , further affecting the model's sensitivity to changes in perchlorate dose, particularly under conditions of low iodide. Thus, The USEPA (2017) BBDR model predicts much greater effects of perchlorate on iodide uptake than any previous version of the model, without justification for re-estimating these parameters rather than using the published values.
Assumptions regarding thyroidal iodide storage
Plots of NHANES 2007-2012 data for non-pregnant women demonstrated little relationship between iodine intake and fT4, even at iodide intake levels below 75 μg/day (Figure A-54 of USEPA, 2017; reproduced in Fig. 5a ). USEPA (2017) used data on the relationship between thyroidal iodide stores (mg) and iodine intake from Delange (2000) , which assumes depletion of fT4 at iodide intake levels below 100 μg/day. As is clear from Fig. 5b , this assumed model behavior at concentrations below 100 μg/day, which drives model predictions at low intakes, is inconsistent with the NHANES data and could result in overprediction of fT4 responses at moderately low intakes of iodide, including the ranges simulated in the USEPA report. This possibility was investigated in this evaluation and the results are discussed in the next section.
Evaluation of BBDR model behavior 3.2.1. Comparison to the Steinmaus et al., (2016) results
In Appendix B of USEPA (2017), a comparison of the predicted changes in both fT4 and TSH from the BBDR model were compared to the results reported by Steinmaus et al. (2016) . The Steinmaus et al. (2016) study was conducted to evaluate the potential for perchlorate exposure to impact thyroid hormone levels in pregnant women (any trimester) in San Diego. They reported an effect of perchlorate on fT4 levels to be similar among women with both low iodine (< 100 μg/day) and normal (100-300 μg/day), with a greater effect of perchlorate observed among pregnant women in the high iodine intake group (> 300 μg/day). They further noted that this result is in contrast to some previous results from NHANES (Blount et al., 2006) and may be due to the overall iodine sufficiency in the studied population or the fairly long time between urine iodine and serum thyroid hormone sample collection (about 9 weeks).
The comparison of the predicted fT4 changes from the BBDR model and the Steinmaus et al. (2016) results associated with changes in perchlorate dose are reported in Figure B -1 of Appendix B of USEPA (2017) and reproduced in Fig. 6 . This comparison, which we were able to reproduce using the USEPA (2017) BBDR model, clearly highlights the differences between the model predictions and the published human data. The USEPA (2017) BBDR model simulations with normal iodine intake (170 μg/day) demonstrate no change in fT4, which is consistent with other studies in which no impact on fT4 has been observed at doses up to 7 μg/kg/day perchlorate (Greer et al., 2002; Braverman et al., 2006) . The USEPA (2017) BBDR model greatly underpredicts the changes in fT4, even in the scenario with low dietary iodine intake (75 μg/day), in comparison to the changes reported by Steinmaus et al. (2016) . This discrepancy raises concerns about the ability of the USEPA (2017) BBDR model to predict changes in fT4 associated with chronic perchlorate exposure during pregnancy.
3.2.2Greer et al., (2002)-14 day human controlled perchlorate dosing study
The Greer et al. (2002) study was conducted to establish the doseresponse in humans for perchlorate inhibition of thyroidal iodide uptake and any short-term effects on thyroid hormones following exposure for male and female volunteers to perchlorate in drinking water at doses of 7, 20, 100 or 500 μg/kg/day for 14 days. The results of this study have previously been relied upon by the USEPA (2005) to derive a reference dose (RfD) and to determine health reference levels (HRLs). The results of this study indicate a decrease in iodide uptake following exposure to a dose of 20 μg/kg/day, but no effect on hormone levels, including fT4 and TSH, at the highest dose tested. A No Observed Effect Level (NOEL) of 7 μg/kg/day was determined based on these results, and an RfD of 0.7 μg/kg/day was adopted, based on NAS recommendations, with the application of an uncertainty factor of 10 for intraspecies variability or sensitive subpopulations.
Consistent with the results of the study, our simulations of the adult exposures reported in Greer et al. (2002) with the BBDR model (Table 1) indicated no significant change in fT4 at doses up to 500 μg/ kg/day. However, predicted concentrations of fT4 are lower than those measured by Greer et al. (2002) . The model simulation reported in Table 1 was run with an iodine intake of 90 μg/day, as this was the value USEPA (2017) used in the Greer_test.m script provided with the BBDR model code. However, 90 μg/day is not consistent with the 170 μg/day value USEPA (2017) reports as representing a sufficient intake and USEPA's (2017) documentation does not indicate why a lower value was used for the individuals in the Greer study. Simulation of iodide uptake inhibition (RAIU) appears to over-predict the reduction in uptake compared to measured values, though the qualitative increasing trend of inhibition with dose behaves appropriately. This discrepancy may result from the low iodine intake chosen by USEPA (2017), or a number of other decisions made in the model revisions, including the reduced Km parameter value. It is unclear why the parameters governing iodide inhibition were altered from previous models that successfully predicted inhibition of iodide in human subjects (Clewell et al., 2007; Merrill et al., 2003; Lumen et al., 2013) . Given that iodide inhibition is the obligatory precursor to all downstream effects in the USEPA's proposed mode of action for perchlorate, it would be expected that any changes to the model that lead to reduced accuracy in the prediction of iodide inhibition would be accompanied by substantial support. However, no such support is provided in USEPA (2017) for the changes in the key parameters and the resulting effect on iodide inhibition predictions.
3.2.3Braverman et al., (2006)-6 month human controlled perchlorate dosing study
The Braverman et al. (2006) study was conducted to determine whether prolonged exposure (6 months) of adults to low levels of perchlorate (0.5, 1.0 or 3.0 mg/day) would perturb thyroid function. The study included a small number of individuals (n = 13); however, iodine levels were comparable with those of the general population. The authors noted the limitations of the small sample size, but concluded that the results suggested that healthy, euthyroid individuals, with normal levels of iodine intake, can tolerate chronic exposure to perchlorate at doses of up to 3 mg/day (approximately 40 μg/kg/day) without any effects on thyroid function, including inhibition of iodine uptake.
The Braverman et al. (2006) study was simulated as part of the current evaluation using the BBDR model and predicted T3 and TSH levels were compared to the reported measurements (Table 2) . fT4 was not compared because it was not clear how to convert the T4 index reported in the study to a concentration and vice versa. As with the Greer et al. (2002) simulation, 90 μg/day was used for iodine intake. Baseline T3 and TSH are similar to the measured values. But, as was seen with fT4, the model fails to predict the observed changes in hormone levels in the adult subjects.
3.2.4Téllez Téllez et al., (2005a), 2005b -Chilean epidemiological study in pregnant women
Téllez Téllez et al. (2005a Téllez et al. ( , 2005b reports the results of a longitudinal epidemiological study among pregnant women from three cities in Chile exposed to concentrations of perchlorate as high as 114 μg/ L in the public drinking water. The focus of the study was to evaluate maternal thyroid function during pregnancy, neonatal thyroid function and developmental status at birth, and breast milk iodine and perchlorate levels during lactation. The National Academy of Sciences (2005) has reviewed this study in the context of health implications for perchlorate ingestion and concluded this study should be considered in the evaluation of the US experience with perchlorate in drinking water. The total iodine nutrition among this cohort was also noted to be similar to that of US pregnant women (Téllez Téllez et al., 2005a) ; therefore, this study should be a key consideration in evaluating the relationship between perchlorate exposure, changes in fT4 in pregnant women and developmental status; however, it was not considered in Stage 2 of the USEPA (2017) assessment because it pre-dated the cutoff used by USEPA in their review (2010) .
Results from this study indicated no effect on thyroid levels in early pregnancy, late pregnancy, or neonates at birth related to perchlorate in drinking water at concentrations up to 114 μg/L. Given these findings, this study provides a reasonable dataset for validating the impact of high perchlorate exposure concentrations in drinking water on potential changes in fT4 or TSH.
We also ran the (USEPA, 2017) BBDR model to simulate the Téllez Téllez et al. (2005a Téllez et al. ( , 2005b drinking water study (Table 3 ). The BBDR model predictions of fT4 for GW 13-16 are consistent with the negative results of the study, though the predicted concentrations are lower than those observed. This is not a strong validation of the model given the weak trend of changes in hormone levels seen in comparisons to other studies.
Summary: evaluation of model behavior
Our simulations of the Greer et al. (2002) and Braverman et al. (2006) studies with the BBDR model indicate that thyroid hormone levels are relatively insensitive to inhibition of thyroid iodine uptake by perchlorate exposures as high as 7 μg/kg/day. Moreover, our simulations of the Téllez Téllez et al. (2005a Téllez et al. ( , 2005b study with the BBDR model do not predict an effect on fT4 from exposures to perchlorate at up to 2 μg/kg/d, consistent with the fact that the exposures were demonstrated to be without effect to pregnant women in the study. However, the USEPA (2017) BBDR modeling analysis (Table 4 , taken from USEPA 2017)predicted population-level changes in fT4 deficiency during the first trimester at perchlorate exposures nearly an order of magnitude lower (0.3 μg/kg/d). This discrepancy suggests that the metric used in the USEPA (2017) approach to assess populationlevel effects of perchlorate, i.e., a 1% or 5% increase the proportion of thyroxinemic mothers in early pregnancy assuming that all individuals have a low (75 μg/day) iodine intake and an inadequate TSH response (pTSH = 0.398 vs. 1), may be overly conservative.
Evaluation of the effect of model assumptions on predicted PODs
In order to assess the potential quantitative impact of some of the uncertainties in the BBDR model, we compared model predictions of percent change in fT4 and TSH for a range of perchlorate concentrations using two alternative parameterizations: (1) the parameterization used by the USEPA (2017) to generate their Tables 3, and (2) replacing the equation for HCGREG with the equation for VCHNG (in order to provide an appropriately coupled response to hCG stimulation of thyroidal iodine uptake and thyroid hormone production), and also setting pTSH = 1 (the nominal value, as opposed to the lower-bound value of 0.398 used by the USEPA). The simulations (Table 5) were performed with the model calibrated to either the median population thyroid hormone levels (using the script medset.r) or a low (thyroxinemic) population defined as fT4 < 10th percentile (using the script lowset.r). When predicting the effect of perchlorate exposure on fT4 for the median population there is not a significant difference between the USEPA results and the alternative parameterization; however, the USEPA model parameterization results in more than a factor of 2 greater sensitivity of TSH levels to perchlorate compared to the alternative parameterization. This difference is primarily due to the change in pTSH. On the other hand, when predicting the effect of perchlorate exposure on hypothyroxemic individuals, both fT4 and TSH responses to perchlorate exposure are significantly lower using the alternative parameterization. Thus, the parameters that were altered in the recent revision of the model (VCHNG, HCGreg, pTSH, KmNiS_p) increase the predicted effect on thyroid hormone levels compared to the expected response with the well-validated precursor event of iodide inhibition. The sensitivity of the prediction to changes in these parameters, and the disconnect between the prediction of iodide inhibition and thyroid hormone levels, calls for better justification -and evaluation -of the given parameter values.
Review of literature linking BBDR results to neurodevelopment outcomes
Chapter 5 of USEPA (2017) focuses on the SAB's recommendation to "Identify literature and conduct analyses to support the model outputs for the downstream steps" from the BBDR's predicted changes in thyroid hormones following exposure to perchlorate. Specifically, Chapter 5 was developed to present the process USEPA (2017) used to identify literature to support the draft approach for derivation of the MCLG for perchlorate. USEPA (2017) states, "Based on the recommendations of previous peer review panels, USEPA assumed that changes in thyroid hormone levels would be expected to lead to neurodevelopmental outcomes", and because of this assumption, a complete systematic review of the body of literature on this topic was not performed. Instead, a "focused review of the published literature" was conducted.
The approach is inconsistent with recent recommendations from the National Research Council (NRC, 2014) regarding systematic review and evidence integration. These recommendations are currently being , 2014b) . The approach applied in these assessments is intended to follow recommendations provided by the National Research Council (NRC, 2013). While development of MCLGs are not part of the IRIS process, the application of systematic review principles in the identification of studies to define the relationship between fT4 and neurodevelopmental effects, is needed. The application of these principles would not only assist in defining the highest quality studies to address a specific research question, they also provide a way to integrate all of the available evidence for the specific research questions raised by the SAB. Systematic reviews include the formulation of a specific question to be addressed and developing a protocol that specifies the methods that will be used to address the question. While a broad research question can lead to a large systematic review, if the research question is limited, such as in the case of perchlorate, then the systematic review becomes more focused. For the USEPA (2017) draft MCLG approach, a systematic review question could have been easily developed based on the SAB recommendation (i.e. "Identify literature and conduct analyses to support the model outputs for the downstream steps") and the protocol would simply be focused on the methods for conducting the systematic review to address this very focused systematic review question in a transparent manner. Transparency being defined by USEPA as "sufficient information will be available to understand the scientific rational behind decisions, as well as, reproduce methods used to identify and evaluate data". However, in the case of the literature identified for consideration in the draft MCLG approach for perchlorate, a well-defined protocol for all steps of the process has not been developed and therefore is inconsistent with the recommendations of the NRC (2013):
"A priori decisions and a predefined protocol are critical during the systematic review process (Berlin and Colditz, 1999; Dickersin, 2002) ; the protocol should describe the following steps: the research question, the search strategy and data sources, the study inclusion and exclusion criteria, the data to be abstracted and derived from the original studies (such as sample size, exposure and outcome assessment methods, and confounders evaluated), the criteria and methods for pooling effect estimates and measures of variability among studies. Systematic reviews and meta-analyses need to be replicable; other investigators following the same steps should be able to identify the same articles, abstract the same data, and reach similar conclusions." At each step of the process for identifying studies for use in the development of the MCLG approach for perchlorate, a detailed set of criteria is needed. For example, if decisions are made to include or exclude any studies, there should be very detailed criteria indicating why studies were included or excluded and it should be specified prior to the initiation of the literature searching process. The criteria for each step should be described in such a way that an independent reviewer could use it to replicate the results of the literature search and review; however, there are several areas in the USEPA (2017) draft MCLG approach for perchlorate where this level of detail is lacking, making it difficult for an independent reviewer to replicate the results.
Systematic review research questions
An overall hypothesis or systematic review research question should be developed that is based on the SAB recommendation to clarify the focus of the review and the linkage between altered maternal fT4 (as predicted by the BBDR model) and the potential for adverse neurodevelopmental effects in offspring. Some additional explanation as to how USEPA arrived at the specific neurodevelopmental outcomes of concern should be provided.
Searching the published literature
While the literature search key words are presented in the USEPA (2017) report, there is a lack of explanation as to the reasoning behind the focus on the outcome of concern. The research question should be used to develop the literature search. The major points used or Table 9 of the USEPA (2017) report, a total number of citations identified should be reported. In addition, the criteria used to screen the original search results should be clearly reported in the document. Essentially, each step of the literature search and review should be reported in such a way that any independent party could easily reproduce the results reported in Chapter 5 of USEPA (2017). The lack of this type of information does not allow the reader to determine if any key studies may have been removed from consideration.
3.4.3. Literature screening approach and selection of key studies USEPA (2017) states that a 3 step approach was used to identify studies for consideration in the development of the approach for derivation of the MCLG for perchlorate. The approaches utilized by USEPA (2017) to identify the epidemiological studies for this evaluation were strictly focused on the appropriateness of the quantitative data for consideration in combination with the output of the BBDR model. Group 2 (studies with categorical analyses only) and Group 3 (studies with analyses not directly compatible with BBDR output) studies were apparently eliminated from consideration in the assessment. While not directly compatible with BBDR modeling output, it is possible that these studies may provide information important in understanding the potential relationship between changes in thyroid hormones and the potential for neurodevelopmental effects, as well as potential key confounders.
While 15 studies were identified in Group 1, only 5 of these were determined by USEPA to include analyses that could be used to connect the results of the BBDR model to incremental changes in adverse neurodevelopmental effects. A clearly defined set of inclusion and exclusion criteria should be provided to clearly convey to the reader why the other 40 studies in Groups 1, 2, and 3 were not considered. In addition, studies that provide no evidence of an inverse relationship between perchlorate exposure and serum thyroid function (e.g. Ghassabian et al., 2014; Modesto et al., 2015; Moleti et al., 2016; Noten et al., 2015) should also be considered to not only understand why these results are in contrast to the potential research question, but also that the overall weight of evidence can be determined. It is possible that the majority of studies provide evidence that critical factors that are not reported in some of the available studies may explain the reported changes in serum thyroid function.
Assessment of study quality and risk of bias
According to recent recommendations from the National Research Council (NRC, 2014), the National Toxicology Program's (NTP) Office of Health Assessment and Translation (OHAT) method for the assessment of study quality and risk of bias of the literature (NTP, 2015) is one method that should be considered for qualitative and quantitative assessments. "An assessment of study quality evaluates the extent to which the researchers conducted their research to the highest possible standards and how a study is reported. Risk of bias is related to the internal validity of a study and reflects study-design characteristics that can introduce a systematic error (or deviation from the true effect) that might affect the magnitude and even the direction of the apparent effect" (NRC, 2014) . Each study meeting inclusion criteria in Group 1, 2, and 3, should be evaluated against a predetermined set of study quality and risk of bias criteria and the results of this evaluation should be presented in the perchlorate MCLG approach report.
Uncertainties critical to characterizing changes in thyroid hormone levels in pregnant women associated with neurodevelopmental changes in offspring
The draft MCLG approach presented in USEPA (2017) to predict doses of perchlorate that would result in per unit changes in neurodevelopmental measures, is, as noted by USEPA (2017), "…dependent upon predictions from the BBDR model, the derivation of the distribution of fT4, and the evaluations of the relationship between fT4 and neurodevelopment. Each of these steps has inherent uncertainties associated with it." A major source of uncertainty is related to the five studies in Group 1 with data that could be used to quantitatively describe the relationship between thyroid hormone levels in early pregnancy and changes in neurodevelopment (Pop et al., 1999 (Pop et al., , 2003 Finken et al., 2013; Korevaar et al., 2016; Vermiglio et al., 2004) . None of these five studies relied upon data from US populations or have been demonstrated to have iodine intake similar to US populations. Yet according to the American Thyroid Association (Alexander et al., 2017) , the reference range of both TSH and fT4 in pregnant women varies depending upon ethnicity. While two studies in Group 1 focused on population groups within the United States, neither were considered for the model because T4 and not fT4 was measured in the pregnant females (Oken et al., 2009) and the relationship between fT4 and neurodevelopment was evaluated in late pregnancy and did not reach statistical significance (Chevrier et al., 2011) . USEPA (2017) (Section 6.5.1) states "there is no reason to believe that the impact of fT4 on neurodevelopment would differ by country, unless there is a substantial difference in iodine intake". While USEPA (2017) does make an effort to evaluate changes in iodine intake in women from various populations, including the US, there are not substantial data reported in the peer-reviewed literature to validate the conclusions that the impact of fT4 on neurodevelopment would differ by population or uncertainty in iodine intake levels would have an impact on the derivation of the MCLG. This is inconsistent with data from the American Thyroid Association (Alexander et al., 2017) that suggest variability in the distribution of thyroid hormone levels across populations and even within ethnicities within a single population.
USEPA (2017) also notes that all five studies used for quantitative analysis relied on a one-time fT4 level during pregnancy (Section 6.5.5). The influence of changes in maternal fT4 on fetal brain development is likely greatest during early pregnancy. The variability in maternal fT4 levels during pregnancy and the lack of measurement of fT4 at time points throughout pregnancy in the studies provides a substantial data gap and lack of information needed to validate some of the assumptions relied upon in the development of the BBDR current model as well as the resulting predictions of the model. As stated in USEPA (2017), "Circulating T3 and T4 levels in an individual are maintained within a narrow range by a negative feedback loop with TSH from the pituitary and TRH from the hypothalamus that operates around a "setpoint." This set-point is different from individual to individual, which generates a population variance in blood levels of thyroid hormone that is considerably broader than the individual variance (Andersen et al., 2002) . Therefore, in euthyroid individuals, serum T4 and T3 fluctuate within a fairly narrow range (about 10% of the population variance), maintained by the negative feedback relationship with serum TSH from the pituitary gland. This normal variation creates a situation where single measures of free or total T4 and TSH are a somewhat imprecise measure of an individual's average T4 and TSH concentrations (Andersen et al., 2002) ." Several other areas of uncertainty are also highlighted by USEPA (2017). Specifically, USEPA (2017) noted that none of the five studies carried forward provided iodine intake levels (Section 6.5.3), which adds significant uncertainty to the estimates. Three of the 5 studies (Pop et al., 1999 (Pop et al., , 2003 Vermiglio et al., 2004 ) also have populations of less than 30 decreasing the statistical power of the studies (section 6.5.4) relied upon for establishing the relationship between changes in fT4 and neurodevelopmental changes. USEPA (2017) also noted uncertainties in regard to the analytical methods used to evaluate fT4 levels and while approaches are being introduced to standardize analytical methods, results at different time points and from different countries may vary considerably due to differences in analytical procedures (USEPA, 2017). USEPA (2017) also notes that "there is uncertainty regarding the true fT4 levels at various percentiles in the distribution around the median output from the BBDR model. This is exemplified by the fact that in this analysis larger unit changes are being seen with increasing percentiles of fT4 in most analyses." Finally, other confounders such as iron deficiency were not considered in the analysis. Iron deficiency in pregnant mothers, which is noted in approximately 18% of pregnant women in the US (Cantor et al., 2015) , may also be associated with hypothyroxinemia (Yu et al., 2015) and failing to directly account for a relationship between iron deficiency and hypothyroxinemia may introduce an uncertainty into this analysis.
While all these uncertainties are noted by USEPA (2017), there is no attempt to adjust the draft MCLG approach in any way to account for these uncertainties. Many of these, especially confounders such as iron deficiency in the study population and a lack of information on iodide intake, can have a significant effect in characterizing changes in thyroid hormone levels associated with changes in neurodevelopmental outcomes. In the absence of adequately accounting for these uncertainties, it is difficult to have confidence that BBDR model predictions of small changes in a specific thyroid hormone (e.g. fT4) may accurately predict the potential for neurodevelopmental effects.
The inadequacy of the USEPA (2017) literature review is substantiated by the comments of the External Peer Review for USEPA's Proposed Approaches to Inform the Derivation of a Maximum Contaminant Level Goal for Perchlorate in Drinking Water (Versar, 2018) . Comments regarding the USEPA (2017) literature search included:
• "The literature search produced ten studies (that assessed maternal serum FT4 concentrations as a continuous measure which did not observe an adverse effect on offspring neurocognition), as well as those in Group 2 that assessed serum FT4 as categorical measures. Although their inclusion may not necessarily be recommended in the final model, comparison of the estimated effects on the various neurocognitive outcomes with and without these may indeed inform the degree of uncertainty inherent in the present model. Several of the studies in Group 2 were able to demonstrate significant adverse outcomes (Berbel et al., 2009 as one excellent example), and also their more global nature would help support the generalizability of the present model."
• "Excluding these studies lessens the power of the total sample size and thus the ability to detect an association between maternal hypothyroxinemia and any of the offspring outcomes, but provides what may be a somewhat exaggerated estimate of the potential adverse effects of perchlorate exposure. This approach is more conservative, to which there are pros and cons of doing so, toward derivation of a perchlorate MCLG. With this approach, the goal is to minimize exposure to the lowest perchlorate concentration associated with any number of adverse outcomes. I would favor the more liberal public health approach, which is inclusion of all available studies, whether they are positive or negative. Although the perchlorate MCLG may be higher, this latter approach would be consistent with using all available evidence to improve the scientific rigor of the proposed study question."
The peer reviewers also suggested a number of additional peer-reviewed studies that they felt should have been considered to inform BBDR modeling of the quantitative relationship between thyroid hormone levels and neurodevelopmental outcomes: • Bath S, Steer C, Golding J, Emmett P, Raymen M. 2013. Effect of inadequate iodine status in UK pregnant women on cognitive outcomes in their children: results from the Avon Longitudinal Study of Parents and Children (ALSPAC). The Lancet, 382(9889): 331-337.
• Bernal J. 2017. Thyroid hormone regulated genes in cerebral cortex development. Journal of Endocrinology, 232(2): R83-R97.
• Casey B, Thom E. 2017. Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. The New England Journal of Medicine, 377 (7): 701.
• • Hales C, Taylor • Taylor In the draft MCLG approach, USEPA (2017) focused on five studies that evaluated the relationship of maternal fT4 and several neurodevelopmental endpoints (IQ, mental development index (MDI), psychomotor development index (PDI), standard deviation of reaction time), based on measurements of fT4 during early pregnancy. Results from previous studies have provided the basis for No Observed Effect Levels (NOELs) for health effects of perchlorate in the development of Reference Doses and currently recommended Health Reference Levels (HRLs), including Greer et al. (2002) in which adult men and women were exposed to perchlorate in drinking water at doses of 0.007, 0.02, 0.1, or 0.5 mg/kg/day for 14 days demonstrated a NOEL for perchlorate inhibition of radioiodide uptake by the thyroid NIS following exposure to 7 μg/kg/day. The point of departure from the Greer et al. (2002) study represents a perchlorate level that precedes the inhibition of iodine uptake by the thyroid. The NAS RfD developed based on the point of departure (POD) from this study is a deviation from the Agency's traditional approach of using a No Observed Adverse Effect Level (NOAEL) for regulatory actions. The NAS's use of a No Observed Effect Level (NOEL) is based on "using a nonadverse effect that is upstream of the adverse effect [which] is a more conservative and health protective approach".
While these studies have not been conducted in pregnant women (the population of interest for the draft MCLG approach), as noted by in USEPA (2017): "…the BBDR model predicts very little difference in non-pregnant and first-trimester response to perchlorate. This likely occurs because the half-life of (organified) iodine in the adult thyroid is around six months, hence the availability of thyroidal iodine in the first trimester pregnant woman is determined to a very large extent by her nutrition and perchlorate exposure several years preceding pregnancy."
This suggests that a comparison of the current modeling results to those from studies conducted in adults should provide insight into the predictions of the model and the conclusions regarding the changes in thyroid hormone levels that may result in neurodevelopmental effects.
The current draft approach for deriving the MCLG assumes any exposure to perchlorate reduces fT4 to some extent (p. 3-17 of USEPA, 2017) . In addition, linear regression analyses conducted to evaluate the relationship between changes in fT4 and neurodevelopmental effects further assumes any change in fT4 results in some risk of neurodevelopmental effects. These assumptions are in contrast to the results from Greer et al. (2002) in which exposures to perchlorate were as high as 500 μg/kg/day and no impact on thyroid hormone levels was observed. This was true for both men and women. In addition, in a study conducted by Braverman et al. (2006) , 6 months of exposure to perchlorate in capsules at doses up to 3 mg/day (approximately 40 μg/kg/day) was reported to have no effect on thyroid function, including inhibition of thyroid iodide uptake as well as serum levels of thyroid hormones, TSH, and Tg in a small group of volunteers.
USEPA (2017) notes (p. 6-16) that from results of the literature review, it appears the relationship between maternal fT4 and fetal brain development has a temporal relationship, with this influence likely being greatest in early pregnancy (i.e. prior to mid-gestation). The focus of the evaluation is on gestational weeks 12, 13, and 16, where the mother's fT4 levels will have the greatest impact on the fetus. This should allow for comparison to the model results in pregnant women to results from previous studies focused on identification of perchlorate concentrations that would impact fT4 levels in adult women, such as the Greer et al. (2002) study.
Based on the BBDR model predictions, USEPA (2017) estimates that a perchlorate dose of 0.3-0.4 μg/kg/day would result in a 1% increase in the proportion of the population with hypothyroxinemia and a perchlorate dose of 2.1-2.2 μg/kg/day would result in a 5% increase in proportion of the population with hypothyroxinemia. These modeling results suggest a potential for a significant change in thyroid hormones, as well as adverse effects on neurodevelopment at doses of perchlorate exposure for which there is evidence that decreases in fT4 are not observed. Based on the mode of action proposed by USEPA (2017), decreases in fT4 and increases in TSH would be prerequisite steps for the potential for neurodevelopmental effects. These changes in hormone levels are not observed in the Greer et al. (2002) study following exposure up to 500 μg/kg/day. The draft MCLG approach suggests population changes in fT4 would be observed that would shift the proportion of pregnant women that would be hypothyroxinemic at doses of perchlorate below the previously defined NOEL (7 μg/kg/day). Table 6 (Table 39 of USEPA, 2017) provides the predicted dose of perchlorate per unit change in neurodevelopmental measure for low iodine intake individuals. Those for IQ are approximately at or above (6.5-45 μg/kg/day) the NOEL from Greer et al. (2002) and are associated with decreases in fT4 of 4.3-18.7%. The doses associated with other neurodevelopmental endpoints are 1.7-3.0 μg/kg/day and are associated with decreases in fT4 of 1.3-2.4%. These percent changes in fT4 are very small and considering the potential uncertainty and variability in measuring fT4 levels, there is a lack of evidence that such small changes in fT4 will result in clinical observations. Reference ranges for fT4 are 0.9-2.5 ng/dL in infants (0-5 days) and 0.9-1.7 ng/ dL in adults (> 20 yrs) (https://www.mayomedicallaboratories.com/ test-catalog/Clinical+and+Interpretive/8725). Thus, for an adult, at the low end of the reference range, we would expect a change from 0.900 to 0.878 ng/dL, a value that given the number of significant figures in the reference value would not be measurable. The dose of perchlorate estimated to result in a 1% or 5% increase in the proportion of hypothyroxinemic pregnant women is even lower, ranging from 0.3 to 2.2 μg/kg/day. USEPA (2017) findings are contrary to multiple studies in adults and pregnant women (Greer et al., 2002; Braverman et al., 2006; Téllez Téllez et al., 2005a , 2005b provide robust evidence that no impact on iodine uptake or thyroid hormone levels would be expected at these dose levels. Based on the mode of action proposed by USEPA (2017), these precursor impacts are necessary to generate the neurodevelopmental effects derived from the BBDR model.
Discussion
A critical review of the (USEPA) 2017 report entitled "Draft Report: Proposed Approaches to Inform the Derivation of a Maximum Contaminant Level Goal for Perchlorate in Drinking Water", as well as the BBDR model that was proposed for use in derivation of the MCLG, was conducted. Overall, conducting this review and assessment of the BBDR model was beset by multiple challenges and the effort highlighted a number of uncertainties in the use of the model. The main challenges that the review presented were due to the complexity of the BBDR model itself. The co-authors of this review, who are widely considered to be experts in the area of PBPK and BBDR model development, found it difficult to evaluate the complex interactions of model parameters and their relationship to the predictions of the model. In our efforts to reproduce simulations provided in USEPA (2017), it was noted that instructions for running the model for different scenarios, and documentation of the rationale for the model parameter values associated with them, were sometimes inadequate; this deficiency, which is inevitable in a complex model, was exacerbated by the number of code scripts required to set the parameters used to generate the various results in the document. As a result, the ability to independently verify all aspects of the model were impeded by uncertainties associated with the steps necessary to reproduce figures and tables in the report, or to perform comparisons of model predictions to data for alternative exposure scenarios or studies.
As suggested by C.A.R. Hoare in his 1980 ACM Turing Award Lecture: "There are two ways of constructing a software design: One way is to make it so simple that there are obviously no deficiencies and the other way is to make it so complicated that there are no obvious deficiencies." By their nature, BBDR models are seldom simple; to the extent that BBDR models attempt to describe complex biological systems they will inherently be difficult to comprehend. The criticisms of the perchlorate PBPK model in this case study are not meant to suggest that the model is incorrect or un-useful, and they should not be taken as criticisms of the utility of BBDR modeling in general. Used appropriately, BBDR models can provide important information for better risk assessment decision-making. The issue that needs to be addressed in each case is whether a BBDR model is fit for the intended purpose of using it in the risk assessment.
The first use of PBPK modeling in risk assessments dates back to the 1980s (USEPA, 1987 ) and yet the application of PBPK modeling to replace default dosimetry remains controversial, primarily due to concerns regarding model uncertainty. To address these concerns, the OMB (2007) memorandum on risk analysis recommended the presentation of results from multiple dose-response approaches to provide a more robust risk characterization. In this scenario, a fit-for-purpose BBDR model can provide information on the most scientifically plausible risk estimate for comparison with the results of default approaches (Clewell et al., 2008) . Consistent with this OMB recommendation, one focus of our evaluation was determining how the results of the BBDR modeling could inform the likelihood that the current perchlorate guideline (USEPA, 2005) , which is based on inhibition of thyroidal iodine uptake in adults, is also protective of concerns regarding neurodevelopmental effects of perchlorate. This question is discussed in the Conclusion.
The current BBDR model that was relied upon for the USEPA (2017) draft approach is an extension of previous models that have been validated and published in the peer-reviewed literature (Clewell et al., 2007; Merrill et al., 2003; Lumen et al., 2013) . Similar values for key parameters have been successfully used across the previous models, yet changes were made in the current model or new parameters added (e.g. VCHNG, HCGreg, pTSH, KmNiS), often with little or no evidence or justification provided to support these revisions in the USEPA (2017) documentation. Additional support for these changes will be needed to provide validation of the current revisions to the BBDR model and to provide confidence in the predictions of changes in fT4 made by the model.
Certainly, confidence in the BBDR model predictions is undermined by the model's inability to simulate the results from the Steinmaus et al. (2016) study. In Appendix B of USEPA (2017), a comparison of the predicted changes in both fT4 and TSH from the BBDR model were compared to the results reported by Steinmaus et al. (2016) (reproduced in Fig. 6 ). The Steinmaus et al. (2016) study was conducted to evaluate the potential for perchlorate exposure to impact thyroid hormone levels in pregnant women in San Diego. This comparison clearly highlights the differences between the model predictions and those from a published study. The baseline BBDR simulations with normal iodine intake (170 μg/day) demonstrate no change in fT4, which is consistent with other studies in which no impact on fT4 has been observed at doses up to 7 μg/kg/day (Greer et al., 2002; Braverman et al., 2006) . The BBDR model underpredicted changes in fT4, even in the scenario with low dietary iodine intake (75 μg/day), when compared to the changes reported by Steinmaus et al. (2016) . This discrepancy calls into question the ability of the model to predict changes in fT4 associated with perchlorate exposure. In particular, the proposed MCLG approach depends on model predictions of small changes in fT4 as low as approximately 1% (Table 6 ) being associated with unit changes in neurodevelopmental endpoints. Predictions of this precision would require a level of model precision that has not been demonstrated by comparisons to existing data.
Many of the changes in fT4 that are predicted by the draft MCLG approach to estimate impact on the population distribution of fT4 and therefore result in per unit changes in neurodevelopmental outcomes are small percent changes (some as low as a 1.3-4.3% change). This would appear to suggest that the extended version of the BBDR model has a capability to estimate small changes in fT4 with a level of precision that is not demonstrated by any adequate validation. In fact, BBDR model predictions of fT4 underpredict observed data in human studies (Tables 1 and 3) by as much as 25-35%. Moreover, considering the variability of fT4 in the populations of interest, there is uncertainty as to whether these slight changes could be measured clinically, considering the greater impact of iodine intake on hormone levels. Considering the lack of data to support critical parameters and assumptions in the model, as well as the impact of the variability of iodine intake on model predictions, it seems crucial that validation of the BBDR model by comparison with observed data be used to provide confidence in the predictions of the BBDR model. However, the BBDR model clearly fails the only comparison that has been conducted (Fig. 6) , with the BBDR model predictions falling outside the bounds of the statistical confidence limits estimated for the Steinmaus et al. (2016) relationship between perchlorate dose and fT4. Each of the components of the BBDR model combined result in compounded uncertainty in the modeling results.
Until additional data are available to validate current extensions of the BBDR model to the pregnant woman, the Greer et al. (2002) and Braverman et al. (2006) studies provide the critical information in determining concentrations of perchlorate that do not result in significant inhibition of iodide uptake and, therefore, impacts on fT4. Based on recommendations from the National Academy of Sciences (2005) , points of departure provided by these studies used in combination with uncertainty factors were considered to be protective of sensitive subpopulations, this approach has previously been relied upon to support guidelines for perchlorate in drinking water under the Safe Drinking Water Act (USEPA, 2008) , and has also been used more recently by JECFA (2011) and EFSA (2014) in their regulation of perchlorate.
Conclusions
We applaud the USEPA for the application of a BBDR model in their draft MCLG approaches, as these models integrate the available science for a compound of interest. However, while the hormone component of the model is a scientific improvement in terms of incorporating the available biology, there is a lack of data to provide critical validation in multiple steps of the proposed approach and to support several assumptions/parameters within the BBDR model. In particular, while no major structural defects in the USEPA (2017) BBDR model were identified, there are a number of uncertainties in the model parameterization that call into question its use for predicting very small changes in clinical hormone values, such as a 1% change in fT4 (Tables 4-6 a Based on the regression analysis for the range of fT4 data within each study. Central beta estimates of the low iodide intake population (= 75 μg/day) are presented. b Hypothyroxinemia defined as fT4 < 10th percentile. c Range based on gestational week used to perform the analysis (12-16 weeks).
available data. Nonetheless, the consistency of the model-predicted PODs based on the epidemiological endpoints (Table 6) , and the relationship of these results with previous risk assessments based on biologically sound precursors (iodide inhibition in thyroid), indicate that the interim health standard would be sufficiently protective against the developmental neurological endpoints of concern, as illustrated in Fig. 7 , which compares the point of departure from the USEPA (2005) IRIS assessment with the PoDs calculated by the BBDR model in the USEPA (2017) report (Table 6 ). The USEPA (2005) RfD (red bar) is protective for all of the endpoints from epidemiological studies and is consistent with a change in population fT4 levels of less than 5%. Beginning with the initial risk characterization for perchlorate (USEPA, 2002) , the fundamental underpinning of the agency's risk assessment approach has been the use of an obligatory precursor as a conservative basis for protecting against downstream health effects. As elaborated in the original documentation (USEPA, 2003) , the effects of perchlorate are mediated by the inhibition of thyroidal iodine uptake by perchlorate. Unless perchlorate concentrations in the blood are sufficient to disrupt iodine uptake, there is no plausible basis for suggesting an effect of perchlorate on thyroid hormone homeostasis or subsequent events leading to developmental or (in the rat) carcinogenic effects. The recent studies suggesting a relationship between perchlorate exposure and decreased fT4 do not impeach this causal relationship. Therefore, until the significant uncertainties in the current BBDR model and draft MCLG approaches can be addressed, USEPA should continue to rely on the RfD approach based on inhibition of thyroidal iodine uptake (USEPA (2005), as recommended by the National Academy of Sciences (2005) for any further regulatory action. The USEPA (2005) RfD includes an intraspecies uncertainty factor of 10 "to protect the most sensitive population, the fetuses of pregnant women who might have hypothyroidism or iodide deficiency." None of the predictions of the BBDR model suggest that this uncertainty factor is inadequate.
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